Valuation: Bonesupport Holding AB

Market Cap 14.88B 1.5B 1.31B 1.24B 1.13B 2.12B 144B 2.13B 5.74B 73.3B 5.61B 5.49B 237B P/E 2026 *
46.3x
P/E 2027 * 29.5x
Enterprise Value 14.34B 1.44B 1.27B 1.2B 1.09B 2.04B 138B 2.05B 5.53B 70.62B 5.41B 5.29B 228B EV / Sales 2026 *
9.6x
EV / Sales 2027 * 7.1x
Free-Float
89.54%
Yield 2026 *
0.64%
Yield 2027 * 0.95%
1 day-12.12%
1 week-12.12%
Current month-8.61%
1 month-8.61%
3 months+0.32%
6 months+2.23%
Current year+8.45%
1 week 21.47
Extreme 21.468
21.47
1 month 21.47
Extreme 21.468
24.43
Current year 19
Extreme 19
28.57
1 year 18.57
Extreme 18.57
31.3
3 years 15.74
Extreme 15.74
35
5 years 3.83
Extreme 3.83
35
10 years 3.83
Extreme 3.83
35
Manager TitleAgeSince
Chief Executive Officer 49 01/09/2025
Director of Finance/CFO 63 01/11/2018
Chief Operating Officer 51 01/12/2021
Director TitleAgeSince
Director/Board Member 68 01/01/2010
Chairman 70 15/12/2016
Chairman 71 14/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
-12.12%-12.12% - - 1.42B
-0.80%+28.07%+705.55%+98.39% 79.4B
-4.54%-4.15%+33.40%-9.65% 78.69B
+2.80%+3.60%-6.34%-27.82% 59.52B
-0.89%+2.11%+7.92%+170.43% 46.58B
+2.49%+0.14%-8.95%+33.71% 46.53B
+0.48%+6.12%+66.48%-11.20% 33.63B
+0.75%-0.39%+50.93%+111.17% 25.11B
-3.56%-0.47%+3.11%+135.37% 22.13B
+0.73%-1.70%+61.19%+100.64% 15.31B
Average -1.37%+4.30%+101.48%+66.78% 45.21B
Weighted average by Cap. -0.38%+6.71%+154.20%+53.71%

Financials

2026 *2027 *
Net sales 1.49B 150M 132M 125M 113M 213M 14.4B 214M 576M 7.36B 563M 551M 23.77B 1.98B 199M 175M 165M 150M 281M 19.06B 283M 763M 9.74B 746M 730M 31.47B
Net income 319M 32.03M 28.17M 26.64M 24.16M 45.41M 3.07B 45.6M 123M 1.57B 120M 118M 5.08B 504M 50.61M 44.51M 42.09M 38.17M 71.75M 4.86B 72.06M 194M 2.48B 190M 186M 8.02B
Net Debt -543M -54.57M -47.99M -45.38M -41.15M -77.35M -5.24B -77.69M -210M -2.68B -205M -200M -8.65B -856M -85.99M -75.62M -71.5M -64.84M -122M -8.25B -122M -330M -4.22B -323M -316M -13.63B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
171
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
227.20SEK
Average target price
356.58SEK
Spread / Average Target
+56.95%

Quarterly revenue - Rate of surprise